1492 Capital Management LLC Takes $973,000 Position in SOPHiA GENETICS SA $SOPH

1492 Capital Management LLC bought a new stake in SOPHiA GENETICS SA (NASDAQ:SOPH) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 208,345 shares of the company’s stock, valued at approximately $973,000. 1492 Capital Management LLC owned approximately 0.31% of SOPHiA GENETICS at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in SOPH. Green Alpha Advisors LLC increased its stake in SOPHiA GENETICS by 10.8% during the fourth quarter. Green Alpha Advisors LLC now owns 45,660 shares of the company’s stock worth $213,000 after acquiring an additional 4,444 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in SOPHiA GENETICS by 24.7% during the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after acquiring an additional 6,205 shares during the last quarter. Savvy Advisors Inc. acquired a new stake in SOPHiA GENETICS during the third quarter worth $48,000. Squarepoint Ops LLC acquired a new stake in SOPHiA GENETICS during the third quarter worth $49,000. Finally, Perkins Capital Management Inc. acquired a new stake in SOPHiA GENETICS during the fourth quarter worth $49,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Insider Buying and Selling at SOPHiA GENETICS

In other news, CEO Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $5.00, for a total value of $87,365.00. Following the completion of the sale, the chief executive officer directly owned 3,646,967 shares of the company’s stock, valued at approximately $18,234,835. The trade was a 0.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 198,859 shares of company stock valued at $968,527 over the last ninety days. Insiders own 4.88% of the company’s stock.

SOPHiA GENETICS Trading Down 3.2%

Shares of NASDAQ SOPH opened at $4.78 on Thursday. SOPHiA GENETICS SA has a twelve month low of $2.59 and a twelve month high of $5.70. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. The stock has a fifty day simple moving average of $4.94 and a 200-day simple moving average of $4.85. The stock has a market capitalization of $327.38 million, a PE ratio of -9.19 and a beta of 0.98.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The firm had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million.

Analyst Upgrades and Downgrades

SOPH has been the subject of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. BTIG Research reissued a “buy” rating and set a $8.00 target price on shares of SOPHiA GENETICS in a research note on Wednesday, May 6th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $7.50.

SOPHiA GENETICS Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.